RxDoctor Payments Data

Manu Sehgal, MD

Geriatric Medicine · Milford, DENPI 1447322060

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 3 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 3 manufacturers reported payments, led by Johnson & Johnson at 36.0% of the total.

$44in general payments, 2019–2025

Across 3 payments — averaging $14.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$16
  • Novo Nordisk$15
  • Novartis$13

What the payments were for

  • Food & beverage$44100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Johnson & Johnson1$16
Novo Nordisk1$15
Novartis1$13

How this compares

Too few geriatric medicine providers in Delawareto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$370,445
Medicare patients
808
Services billed
4,048

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban301$283,577
JardianceEmpagliflozin133$166,245
OzempicSemaglutide102$158,803
TrulicityDulaglutide51$93,512
FarxigaDapagliflozin Propanediol64$73,342
RexultiBrexpiprazole60$64,702
MounjaroTirzepatide43$53,794
Trelegy ElliptaFluticasone/Umeclidin/Vilanter30$26,211
XareltoRivaroxaban33$26,143
MyrbetriqMirabegron33$24,214
Olmesartan Medoxomil492$15,890
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr20$14,695
Atorvastatin Calcium912$13,363
BrilintaTicagrelor18$13,326
Breo ElliptaFluticasone/Vilanterol12$12,818

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$15$158,803102 claims
Johnson & JohnsonXarelto$16$26,14333 claims
NovartisEntresto$13$9,17514 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few geriatric medicine providers in Delawareon file to place this against a meaningful peer group, so we don't.

Other geriatric medicine in Milford

See the full list for Delaware

Where these figures come from

Is this you, or does something look wrong? →